# Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19

> **NCT04635943** · PHASE2 · COMPLETED · sponsor: **Universidad Peruana Cayetano Heredia** · enrollment: 186 (actual)

## Conditions studied

- Covid19
- Coronavirus Infection
- SARS-CoV Infection

## Interventions

- **DRUG:** Ivermectin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04635943
- **Lead sponsor:** Universidad Peruana Cayetano Heredia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-29
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2021-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635943, "Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04635943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*